News & Events

800,000 USD grant received from Chief scientist

03 May|

Preparing for Phase IIa

03 May|

Clinical trial: Phase I Dose Escalation completed successfully with exciting results

01 Apr|

To date, 23 patients with advanced/metastatic solid tumors have been enrolled (3+3 protocol).

Toxicity: MTD has not been reached. Treatment was well-tolerated with no cumulative toxicity.
Pharmacokinetic analysis: AUC, Cmax and t½ were calculated and were dose-dependent and approximately linear.
Efficacy: 5 of 15 evaluable patients have been treated for at least 3 cycles and were considered